middl
east
respiratori
syndrom
mer
coronaviru
merscov
infecti
viru
first
report
merscov
genom
encod
four
major
structur
protein
among
spike
protein
key
role
viral
infect
pathogenesi
receptorbind
domain
rbd
protein
contain
critic
neutral
domain
import
target
develop
mer
vaccin
therapeut
review
describ
relev
featur
merscov
sprotein
rbd
summar
recent
advanc
develop
merscov
rbdbase
vaccin
therapeut
antibodi
illustr
potenti
challeng
strategi
improv
efficaci
merscov
particularli
neutral
antibodi
neutral
merscov
infect
detect
sera
dromedari
camel
number
countri
region
high
posit
detect
rate
addit
cameltocamel
transmiss
merscov
cameltohuman
transmiss
occur
via
direct
indirect
contact
sick
anim
high
preval
merscov
infect
camel
worker
particularli
saudi
arabia
follow
infect
individu
humantohuman
transmiss
merscov
occur
frequent
mainli
contribut
commun
healthcareassoci
outbreak
infect
human
merscov
mainli
occur
lower
respiratori
tract
caus
sever
respiratori
symptom
lead
failur
respiratori
system
andor
organ
rare
occas
human
intestin
tract
altern
infect
rout
antimerscov
antibodi
includ
neutral
antibodi
found
infect
patient
persist
present
antibodi
month
diseas
outbreak
antibodi
respons
particularli
neutral
antibodi
respons
crucial
factor
success
treatment
merscov
infect
human
regard
plasma
convalesc
merscovinfect
patient
use
treatment
merscov
infect
clinic
requir
neutral
antibodi
titer
eg
plaquereduct
neutral
titer
prnt
obtain
effect
therapeut
result
current
human
polyclon
igg
antibodi
produc
transchromosom
cattl
immun
merscov
vaccin
well
sever
vaccin
candid
http
http
test
human
clinic
trial
howev
yet
vaccin
therapeut
agent
approv
prevent
treatment
mer
indic
need
develop
novel
effect
vaccin
therapeut
merscov
infect
follow
review
briefli
describ
merscov
spike
protein
receptorbind
domain
rbd
summar
recent
advanc
develop
rbdbase
merscov
vaccin
therapeut
well
potenti
challeng
futur
expect
success
develop
merscov
belong
genu
betacoronaviru
sever
acut
respiratori
syndrom
sar
cov
merscov
positivesens
singlestrand
rna
viru
genom
encod
structur
protein
envelop
e
membran
nucleocapsid
n
well
nonstructur
protein
translat
open
read
frame
orf
sever
accessori
protein
figur
b
function
protein
elucid
exampl
known
endonucleolyt
rnacleavag
function
promot
infecti
viru
particl
product
human
cell
also
particip
effici
viral
replic
interact
viral
rna
probabl
via
cisact
element
termin
code
region
evid
indic
necessari
interferon
resist
viral
pathogenesi
wherea
nidovir
uridylatespecif
endoribonucleas
structur
recent
resolv
activ
may
mediat
catalyt
residu
oligomer
assembl
rnabind
effici
addit
protein
recogn
bind
doublestrand
ds
rna
four
residu
protein
might
crucial
stabil
also
inhibit
protein
kinas
rmediat
antivir
stress
respons
mediatedinhibit
stressgranul
format
may
facilit
viral
translat
result
effici
merscov
replic
merscov
protein
interfer
innat
immun
respons
infect
virus
virus
virus
event
configur
one
two
three
rbd
rotat
rbd
determin
expos
apex
complex
access
interact
figur
virus
figur
structur
basi
merscov
sprotein
interact
structur
data
complex
merscov
sprotein
rbd
bound
protein
data
bank
pdb
id
merscov
rbd
core
color
blue
rbm
color
red
color
green
rbm
residu
directli
involv
bind
shown
stick
dipeptidyl
peptidas
rbd
receptorbind
domain
rbm
receptorbind
motif
spike
protein
figur
model
merscov
sprotein
trimer
bound
model
gener
superimpos
merscov
rbd
structur
merscov
sprotein
complex
pdb
id
onto
rbd
structur
merscov
sprotein
trimer
one
rbd
pdb
id
b
two
rbd
pdb
id
c
three
rbd
pdb
id
stand
conform
merscov
sprotein
trimer
color
gray
three
rbd
color
red
blue
green
three
dimer
color
plum
orang
yellow
dipeptidyl
peptidas
pdb
protein
data
bank
rbd
receptorbind
domain
spike
protein
function
structur
sprotein
rbd
demonstr
import
target
develop
vaccin
therapeut
agent
merscov
number
mer
vaccin
develop
base
viral
rbd
includ
nanoparticl
viruslik
particl
vlp
recombin
protein
protect
efficaci
evalu
anim
model
includ
mice
adenoviru
direct
express
human
mice
nonhuman
primat
nhp
featur
rbdbase
vaccin
term
function
antigen
immunogen
protect
abil
shown
tabl
middl
east
respiratori
syndrom
mer
coronaviru
cov
infecti
viru
first
report
june
merscov
may
infect
peopl
age
older
age
underli
comorbid
diabet
mellitu
renal
diseas
respiratori
diseas
heart
diseas
hypertens
delay
confirm
late
diagnosi
factor
affect
mer
diseas
outcom
mortal
sex
could
factor
mer
epidemiolog
male
seem
affect
femal
merscov
infect
women
pregnanc
advers
outcom
fetal
mortal
howev
limit
number
pediatr
merscov
infect
occur
end
decemb
laboratoryconfirm
mer
infect
report
global
countri
lead
death
mortal
among
infect
report
saudi
arabia
mortal
individu
http
wwwemrowhointhealthtopicsmerscovmersoutbreakshtml
largest
mer
outbreak
outsid
saudi
arabia
occur
south
korea
case
death
recent
mer
case
report
south
korea
unit
kingdom
malaysia
addit
saudi
arabia
unit
arab
emir
oman
http
wwwwhointemergenciesmerscoven
merscov
thought
origin
bat
merslik
virus
isol
bat
use
lower
effici
receptor
cell
entri
merscov
isol
human
dromedari
camel
potenti
intermedi
longterm
evolut
merscov
season
zoonot
transfer
viru
human
antibodi
specif
host
cellular
proteas
activ
viral
entri
although
evid
initi
indic
cellular
furin
activ
protein
subsequ
result
demonstr
evid
involv
furin
viral
entri
receptor
vari
among
differ
host
speci
merscov
thought
use
multipl
pathway
enabl
rapid
adapt
speciesspecif
variat
addit
merscov
bind
sialic
acid
via
subunit
protein
util
membraneassoci
kda
glucoseregul
protein
attach
target
cell
suggest
protein
may
also
role
virion
attach
structur
merscov
rbd
alon
complex
determin
figur
rbd
foldrich
tertiari
structur
consist
core
receptorbind
motif
rbm
stabil
provid
four
disulfid
bond
two
glycan
number
rbd
residu
locat
interfac
critic
role
bind
structur
analysi
merscov
trimer
protein
identifi
specif
featur
rbd
complex
notabl
prefus
conform
trimer
individu
rbd
either
buri
lie
state
expos
stand
state
flexibl
presum
facilit
recognit
structur
studi
reveal
four
strimer
conform
state
rbd
either
tightli
pack
membranedist
apex
rotat
receptoraccess
conform
suggest
fusion
initi
sequenti
rbd
event
configur
one
two
three
rbd
rotat
rbd
determin
expos
apex
complex
access
interact
figur
merscov
protein
import
role
viral
pathogenesi
determin
host
tropism
entri
host
cell
protein
contain
subunit
n
terminu
subunit
c
terminu
subunit
compos
ntermin
domain
ntd
rbd
rbd
key
role
mediat
bind
merscov
cell
express
dipeptidyl
peptidas
receptor
enabl
viru
enter
target
cell
fuse
cell
membran
format
fusion
core
figur
protein
requir
host
cellular
proteas
activ
viral
entri
although
evid
initi
indic
cellular
furin
activ
protein
subsequ
result
demonstr
evid
involv
furin
viral
entri
receptor
vari
among
differ
host
speci
merscov
thought
use
multipl
pathway
enabl
rapid
adapt
speciesspecif
variat
addit
merscov
bind
sialic
acid
via
subunit
protein
util
membraneassoci
kda
glucoseregul
protein
attach
target
cell
suggest
protein
may
also
role
virion
attach
structur
merscov
rbd
alon
complex
determin
figur
rbd
foldrich
tertiari
structur
consist
core
receptorbind
motif
rbm
stabil
provid
four
disulfid
bond
two
glycan
number
rbd
residu
locat
interfac
critic
role
bind
structur
analysi
merscov
trimer
protein
identifi
specif
featur
rbd
complex
notabl
prefus
conform
trimer
individu
rbd
either
buri
lie
state
expos
stand
state
flexibl
presum
facilit
recognit
structur
studi
reveal
four
strimer
conform
state
rbd
either
tightli
pack
membranedist
apex
rotat
receptoraccess
conform
suggest
fusion
initi
sequenti
rbd
merscov
rbd
core
color
blue
rbm
color
red
color
green
rbm
residu
directli
involv
bind
shown
stick
dipeptidyl
peptidas
rbd
receptorbind
domain
rbm
receptorbind
motif
spike
protein
function
structur
sprotein
rbd
demonstr
import
target
develop
vaccin
therapeut
agent
merscov
number
mer
vaccin
develop
base
viral
rbd
includ
nanoparticl
viruslik
particl
vlp
recombin
protein
protect
efficaci
evalu
anim
model
includ
mice
adenoviru
direct
express
human
mice
nonhuman
primat
nhp
featur
rbdbase
vaccin
term
function
antigen
immunogen
protect
abil
shown
tabl
function
structur
sprotein
rbd
demonstr
import
target
develop
vaccin
therapeut
agent
merscov
number
mer
vaccin
develop
base
viral
rbd
includ
nanoparticl
viruslik
particl
vlp
recombin
protein
protect
efficaci
evalu
anim
model
includ
mice
adenoviru
direct
express
human
mice
nonhuman
primat
nhp
featur
rbdbase
vaccin
term
function
antigen
immunogen
protect
abil
shown
tabl
solubl
nanoparticl
vaccin
form
escherichia
coli
rnamedi
fold
rbdferritin
fr
hybrid
elicit
robust
rbdspecif
antibodi
cellular
immun
respons
mice
produc
antisera
effect
block
bind
rbd
vitro
adjuv
alum
squalenebas
significantli
augment
antibodi
titer
tcell
respons
induc
rbdfr
nanoparticl
vaccin
engin
without
ssg
linker
similarli
chimer
spheric
vlp
svlp
vaccin
express
merscov
rbd
induc
specif
antibodi
cellular
immun
respons
mice
prevent
pseudotyp
merscov
entri
suscept
cell
protect
efficaci
two
type
mer
vaccin
yet
seem
investig
viralchalleng
anim
model
recombin
vaccin
involv
rbd
subunit
extens
studi
protect
merscov
infect
merscovsuscept
anim
model
recombin
rbd
rrbd
fragment
residu
express
insect
cell
elicit
antibodi
respons
product
neutral
antibodi
mice
nhp
give
incomplet
protect
merscovchalleng
nhp
allevi
pneumonia
clinic
manifest
well
reduct
viral
load
lung
trachea
oropharyng
swab
merscov
sprotein
rbd
fragment
contain
residu
identifi
critic
neutral
domain
treatment
regimen
involv
two
dose
fusion
fragment
fc
region
human
igg
four
week
apart
abl
induc
strong
longterm
antibodi
respons
includ
product
neutral
antibodi
mice
respons
significantli
greater
singl
dose
two
dose
interv
one
two
three
week
rrbd
singl
multipl
mutat
correspond
sprotein
sequenc
merscov
strain
isol
human
camel
also
studi
rrbd
bind
rbdspecif
neutral
monoclon
antibodi
mab
highli
immunogen
elicit
product
antibodi
mice
crossneutr
multipl
mer
pseudovirus
live
merscov
trimer
rbdfd
protein
form
fuse
merscov
rbd
fragment
residu
foldon
trimer
motif
bind
strongli
elicit
robust
longterm
respons
product
merscov
antibodi
neutral
antibodi
mice
protect
mice
merscov
infect
protect
provid
exist
subunit
vaccin
base
wildtyp
merscov
rbd
complet
surviv
rate
mice
merscov
challeng
rbdfd
howev
variant
rbd
vaccin
produc
mask
nonneutr
epitop
residu
glycan
probe
function
bind
antigen
bind
four
potent
merscov
rbdspecif
neutral
mab
vaccin
significantli
greater
efficaci
wildtyp
rbd
vaccin
fulli
protect
lethal
merscov
challeng
immun
mice
demonstr
possibl
develop
rbdbase
merscov
vaccin
high
efficaci
antibodi
gener
greater
neutral
activ
merscov
infect
nonrbd
antibodi
prophylact
therapeut
efficaci
rbdtarget
antibodi
test
mice
mice
nhp
earlier
review
describ
antivir
mechan
vivo
protect
crystal
structur
previous
report
merscov
rbdspecif
mab
includ
mous
mab
human
mab
review
focu
newli
report
antibodi
target
merscov
sprotein
rbd
newli
identifi
featur
exist
mab
describ
previous
tabl
rbdtarget
human
mab
extens
report
mab
neutral
pseudotyp
live
merscov
vitro
shown
protect
merscov
infect
anim
model
vivo
structur
sever
mab
antigenbind
fragment
fab
singlechain
variabl
fragment
scfv
complex
rbd
known
figur
bind
mab
rbd
involv
two
major
recognit
mode
bind
rbd
residu
contact
overlap
case
bind
rbd
residu
outsid
interfac
seen
tabl
infect
anim
model
vivo
structur
sever
mab
antigenbind
fragment
fab
singlechain
variabl
fragment
scfv
complex
rbd
known
figur
bind
mab
rbd
involv
two
major
recognit
mode
bind
rbd
residu
contact
overlap
case
bind
rbd
residu
outsid
interfac
seen
tabl
human
mab
recogn
distinct
region
rbd
mab
synergist
effect
neutral
pseudotyp
merscov
vitro
much
lower
halfmaxim
inhibitori
concentr
use
combin
separ
analysi
crystal
structur
indic
bind
rbd
site
neutral
recognit
epitop
almost
complet
overlap
site
seen
previous
merscov
rbdtarget
neutral
mab
mab
protect
mice
merscov
challeng
prevent
therapeut
significantli
lower
lung
viru
titer
rna
copi
number
day
postchalleng
higher
surviv
rate
prechalleng
vaccin
postchalleng
vaccin
rel
control
mice
treat
irrelev
mab
human
mab
isol
mer
survivor
via
construct
phagedisplay
antibodi
librari
peripher
b
cell
crystal
structur
analysi
indic
bind
merscov
sprotein
rbd
residu
involv
receptor
bind
thu
interf
rbd
bind
figur
mab
prophylact
therapeut
inhibit
merscov
replic
common
marmoset
result
significantli
improv
outcom
reduc
human
mab
recogn
distinct
region
rbd
mab
synergist
effect
neutral
pseudotyp
merscov
vitro
much
lower
halfmaxim
inhibitori
concentr
ic
use
combin
separ
analysi
crystal
structur
indic
bind
rbd
site
neutral
recognit
epitop
almost
complet
overlap
site
seen
previous
merscov
rbdtarget
neutral
mab
mab
protect
mice
merscov
challeng
prevent
therapeut
significantli
lower
lung
viru
titer
rna
copi
number
day
postchalleng
higher
surviv
rate
prechalleng
vaccin
postchalleng
vaccin
rel
control
mice
treat
irrelev
mab
human
mab
isol
mer
survivor
via
construct
phagedisplay
antibodi
librari
peripher
b
cell
crystal
structur
analysi
indic
bind
merscov
sprotein
rbd
residu
involv
receptor
bind
thu
interf
rbd
bind
figur
mab
prophylact
therapeut
inhibit
merscov
replic
common
marmoset
result
significantli
improv
outcom
reduc
lung
diseas
compar
unvaccin
control
undetect
viru
titer
day
postchalleng
probebas
singlebcel
clone
strategi
use
isol
mab
patient
convalesc
mer
well
isol
mab
nhp
immun
merscov
fulllength
dna
protein
antibodi
neutral
activ
pseudotyp
live
merscov
among
potent
pseudotyp
merscov
strain
neutral
ic
valu
rang
crystalstructur
analysi
fabrbd
complex
indic
mab
bind
rbd
expos
posit
rbd
bind
overlap
residu
figur
c
addit
prophylact
protect
mice
merscov
infect
result
detect
viral
replic
lung
three
day
postchalleng
fatal
day
observ
human
mab
also
neutral
pseudotyp
merscov
notabl
display
synergist
neutral
combin
merscov
sprotein
rbdtarget
mab
well
sprotein
ntdtarget
mab
case
dramat
reduct
ic
compar
individu
mab
structur
analysi
complex
reveal
bind
rbd
outsid
interfac
rather
compet
figur
unlik
bind
rbd
regardless
conform
state
within
trimer
bind
rbd
stand
posit
epitop
readili
expos
access
thu
display
uniqu
epitop
specif
unusu
mechan
action
involv
indirect
interfer
bind
conform
chang
may
explain
observ
synergist
neutral
combin
mab
singledomain
antibodi
fragment
vhh
nanobodi
antigenrecognit
region
camelid
heavychainonli
antibodi
hcab
contain
light
chain
vhh
easili
express
high
yield
intrins
stabil
strong
bind
affin
specif
target
antigen
therefor
develop
import
therapeut
tool
viral
infect
includ
merscov
four
vhh
identifi
bone
marrow
cell
dromedari
camel
immun
modifi
vaccinia
viru
mva
express
merscov
protein
challeng
merscov
vhh
bind
merscov
protein
low
k
valu
nm
recogn
epitop
residu
rbd
neutral
merscov
prnt
four
monomer
vhh
fuse
ctermin
human
tag
gener
four
hcab
higher
bind
affin
longer
halflif
free
vhh
studi
protect
efficaci
show
mice
inject
monomer
per
mous
lose
weight
die
within
seven
day
postinfect
possibl
short
halflif
vhh
howev
mice
inject
per
mous
extend
halflif
day
protect
merscov
complet
viral
titer
patholog
chang
lung
viral
challeng
mice
immun
llama
recombin
rbd
fragment
residu
fuse
ctermin
human
igg
fc
tag
construct
vhh
librari
use
gener
monomer
vhh
human
fcfuse
vhh
vhh
express
yeast
express
system
high
puriti
bind
rbd
high
affin
recogn
conform
epitop
residu
interfac
block
bind
rbd
vhh
particularli
potent
crossneutr
pseudotyp
merscov
strain
isol
differ
countri
host
time
period
importantli
fcfuse
significantli
improv
serum
halflif
singledos
treatment
mice
agent
complet
protect
lethal
merscov
challeng
singledomain
vhh
demonstr
feasibl
develop
costeffect
potent
broadspectrum
therapeut
antibodi
merscov
infect
compar
vaccin
base
merscov
fulllength
protein
potenti
attenu
neutral
activ
enhanc
immun
patholog
vaccin
develop
merscov
sprotein
rbd
safer
caus
immunolog
toxic
eosinophil
immun
enhanc
moreov
rbdbase
therapeut
antibodi
gener
potent
nonrbd
antibodi
henc
rbdbase
vaccin
therapeut
antibodi
potenti
develop
effect
tool
prevent
treat
merscov
infect
despit
acknowledg
advantag
issu
associ
rbdbase
intervent
need
address
exampl
rbd
high
level
pressur
posit
select
mutat
occur
bind
interfac
might
reduc
efficaci
treatment
one
possibl
way
avoid
effect
delay
emerg
escap
mutant
combin
rbdtarget
therapeut
target
region
protein
combin
antibodi
recogn
distinct
epitop
within
rbd
combinatori
strategi
could
also
dramat
reduc
antibodi
neutral
dose
provid
feasibl
mean
combat
continu
threat
merscov
recent
advanc
made
structureguid
design
antimerscov
intervent
structur
design
inhibitor
proteas
demonstr
potenc
merscov
also
structur
design
sprotein
trimer
optim
prefus
conform
shown
elicit
product
high
titer
antimerscov
neutral
antibodi
inde
base
previou
studi
structur
design
merscov
rbd
nonneutr
epitop
rbd
mask
refocu
immunogen
rbd
neutral
epitop
thu
enhanc
abil
confer
immun
protect
result
structurebas
studi
help
inform
design
innov
rbdbase
antimerscov
vaccin
therapeut
improv
efficaci
